{"pub_date": "2016-04-07T00:00:00Z", "subsection_name": "DealBook", "lead_paragraph": "William A. Ackman said the drug company Valeant was undervalued and had potential but its decline had affected his firm, Pershing Square.", "print_page": "2", "document_type": "article", "byline": {"person": [{"rank": 1, "organization": "", "firstname": "Landon", "lastname": "THOMAS", "role": "reported", "qualifier": "Jr"}], "original": "By LANDON THOMAS Jr"}, "multimedia": [{"width": 190, "height": 126, "url": "images/2016/04/07/business/07db-ackman/07db-ackman-thumbWide.jpg", "subtype": "wide", "legacy": {"wide": "images/2016/04/07/business/07db-ackman/07db-ackman-thumbWide.jpg", "widewidth": "190", "wideheight": "126"}, "type": "image"}, {"width": 600, "height": 392, "url": "images/2016/04/07/business/07db-ackman/07db-ackman-articleLarge.jpg", "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "392", "xlarge": "images/2016/04/07/business/07db-ackman/07db-ackman-articleLarge.jpg"}, "type": "image"}, {"width": 75, "height": 75, "url": "images/2016/04/07/business/07db-ackman/07db-ackman-thumbStandard.jpg", "subtype": "thumbnail", "legacy": {"thumbnail": "images/2016/04/07/business/07db-ackman/07db-ackman-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image"}], "section_name": "Business Day", "headline": {"print_headline": "Business Briefing; Ackman Defends Holding in Beleaguered Valeant", "main": "Ackman Defends Pershing Square\u2019s Large Stake in Valeant"}, "source": "The New York Times", "blog": [], "word_count": "510", "web_url": "http://www.nytimes.com/2016/04/07/business/dealbook/ackman-defends-pershing-squares-large-stake-in-valeant.html", "slideshow_credits": null, "news_desk": "Business", "type_of_material": "News", "snippet": "William A. Ackman said the drug company Valeant was undervalued and had potential but its decline had affected his firm, Pershing Square.", "_id": "57054e9638f0d86865ca518f", "abstract": "Pershing Square Capital Management owner William A Ackman admits he underestimated complexities surrounding Valeant Pharmaceuticals; Ackman's hedge fund was negatively impacted when troubled drug firm's stock fell sharply last quarter. ", "keywords": [{"rank": "1", "name": "organizations", "value": "Pershing Square Capital Management", "is_major": "Y"}, {"rank": "2", "name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y"}, {"rank": "3", "name": "persons", "value": "Ackman, William A", "is_major": "Y"}, {"rank": "4", "name": "subject", "value": "Hedge Funds", "is_major": "N"}, {"rank": "5", "name": "persons", "value": "Pearson, John Michael (1959- )", "is_major": "N"}]}